retatrutide clinical trials efficacy The Effect of on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity Retatrutide FDA Approval Status: July

This product is not intended to diagnose, treat, cure or prevent any disease

The body has adapted to the medication, and weight loss benefits become increasingly apparent

It is not an FDA-approved treatment for obesity

Sequence is a telehealth provider solely focused on GLP-1 prescriptions

The not-so-good news

Dosing Comparison# Retatrutide Dosing# Based on Phase 2 trial data: Route : Once-weekly subcutaneous injection Dose range studied : 0.5 mg to 12 mg weekly Optimal dose : 12 mg weekly showed maximum efficacy in Phase 2 Titration : Gradual dose escalation over several weeks to manage GI tolerability Tirzepatide Dosing# Established FDA-approved dosing: Route : Once-weekly subcutaneous injection Starting dose : 2.5 mg weekly for 4 weeks Maintenance range : 5 mg, 10 mg, or 15 mg weekly Titration : 2.5 mg increments every 4 weeks to target dose Available formulations : Prefilled pens (Mounjaro/Zepbound) Tirzepatide's established titration protocol and prefilled pen delivery system offer practical advantages in clinical use